Robert Hershberg, M.D, Ph.D., is a member of Silverback Therapeutics’ board of directors. He recently served as executive vice president and head of business development and global alliances at Celgene (acquired by Bristol-Myers Squibb in 2019). He was employed in positions of ascending responsibility at Celgene since joining the company in 2014, including his role as chief scientific officer. Prior to joining Celgene, Dr. Hershberg was the co-founder and chief executive officer of VentiRx Pharmaceuticals. Earlier in his career, he was the chief medical officer of Dendreon and vice president of medical genetics at Corixa. Dr. Hershberg also serves on the Boards of Adaptive Biotechnologies and Nanostring Technologies. He is a clinical faculty member at the University of Washington School of Medicine, and holds an M.D. from UCLA and a Ph.D. from the Salk Institute.